Q-omics provides the consensus-scored NXPH1 profile across patient tissues and cancer cell-line models. NXPH1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NXPH1 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NXPH1 RNA expression shows 11,662 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where NXPH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXPH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXPH1 survival associations across molecular data types. NXPH1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXPH1 RNA expression–survival associations across cancer types. High NXPH1 expression shows unfavorable associations in HNSC and LUAD, but favorable associations in PAAD, SCLC, LGG and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for NXPH1 RNA expression.
This table summarizes NXPH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NXPH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXPH1 shows higher tumor expression in COAD, BRCA, LUAD, UCEC, LUSC and STAD. The COAD box plot shows higher NXPH1 RNA expression in tumor versus normal tissue (log2 FC = +0.157, t-test p < 0.001).
This table shows molecular features associated with NXPH1 in patient tissues and cancer cell lines. In patient samples, NXPH1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NXPH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
